Thomas Blankenburg

Author PubWeight™ 4.73^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.	J Clin Oncol	2005	1.42
2	Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.	Clin Lung Cancer	2006	0.86
3	Influence of NaCl 0.9% Infusion during Plasmapheresis on IgG Content in Plasma.	Transfus Med Hemother	2010	0.85
4	A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.	Clin Lung Cancer	2003	0.85
5	Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.	Clin Lung Cancer	2005	0.77
6	A relative survival model for clustered responses.	Biom J	2008	0.75
7	Survival of patients in clinical stages I-IIIb of non-small-cell lung cancer treated with radiation therapy alone. Results of a population-based study in Southern Saxony-Anhalt.	Strahlenther Onkol	2004	0.75
8	Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer.	Clin Lung Cancer	2006	0.75
9	Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.	Onkologie	2005	0.75